الفهرس | Only 14 pages are availabe for public view |
Abstract This study was conducted to compare the safety and efficacy of rivaroxaban as compared to warfarin in treating acute lower limb DVT. A 130 patients were treated with both drugs 65 patients each and were observed for the resulting outcomes of thrombus resolution and development of complications over 6 months of follow up starting from March 2021 to April 2022. They were diagnosed with acute lower limb DVT using Wells score and doppler ultrasonography to confirm the diagnosis. For the entire study patients were followed up for the development of complications and for thrombus resolution. To do so we notified the patients to return for a follow up visit at 3 and 6 months of the start of their treatment and we repeated the doppler ultrasonography at each visit and the size of the thrombus was observed and compared with the initial thrombus size at the time of diagnosis. Moreover, we recorded any events of bleeding reported by the studied individuals and D-dimer, V/Q perfusion scintigraphy, MDCT angiography and/or pulmonary angiography were ordered for those who were suspected to develop pulmonary embolism. We found that there is no statistical significance between rivaroxaban and warfarin as regarding their efficacy and safety in treating acute lower limb DVT. However, we can safely say that rivaroxaban has an upper hand to warfarin as it does not require a bridge therapy with enoxaparin or require laboratory monitoring and dose adjustment. |